AZ inks clot-fighter deal in India; NSCLC meds forecast to hit $7.9B by 2020; Adherence lags in heart attack patients;

> AstraZeneca ($AZN) continued its quest to build sales for its clot-fighting drug Brilinta (ticagrelor), tapping Sun Pharmaceutical to market the med in India under a new brand name, Axcer. Report

> The market for non-small cell lung cancer treatments is set to grow to $7.9 billion by 2020 as new meds Opdivo, from Bristol-Myers Squibb ($BMY), and Keytruda, from Pfizer ($PFE), win new indications and rack up sales gains, GBI Research says. Report

> Many patients who survive a heart attack don't take prescribed meds as directed afterward. Report

> Shire ($SHPG) won European approval for its constipation drug Resolor for men with chronic constipation; it's already approved for women. Report

> Sprout Pharmaceuticals' third run at FDA approval for its women's libido drug flibanserin hit a snag Tuesday with agency reviewers' reporting continued concerns that its risks outweigh its benefits. Report

> Roche ($RHHBY) remains the world's biggest seller of cancer drugs, but growth in its portfolio is slowing. Report

> Merck's ($MRK) combination cholesterol drug Liptruzet, which marries its Zetia drug with the active ingredient in Pfizer's Lipitor, hit the FDA shortage list after the company decided to withdraw the product. Report

And Finally... High-profile investors racked up gains this week on news out of the American Society of Clinical Oncology meeting. Report

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.

Bristol-Myers Squibb and Pfizer's Eliqus has taken the U.S. warfarin alternative market by storm, but can afib screening amp it up even more?